中文 English

RISCare® Breast Cancer /Ovarian Cancer Susceptibility Gene Detection

Detection method

The next-generation sequencing (NGS) used in this assay, compared to PCR and Sanger sequencing methods, is able to simultaneously detect mutations in the full coding sequence of multiple genes. A single test can provide more information on clinical diagnosis and treatment.

Test significance

To evaluate the risk of cancer for the patient and provide the basis for clinical diagnosis and treatment.

Product advantage

Standardized: All detected genes are derived from NCCN guidelines and ASCO recommendations.

Comprehensive: Comprehensive detection of all coding regions and some intron regions of 19 genes. 

Precision: Based on NGS, the average sequencing depth is at least 1,000X, and the target gene coverage is 100%. 

Professional : Professional genetic counseling teams provide clinical and genetic counseling services.

Detection of genes

Tumor genes(18)

  • ATM
  • BRCA1
  • BRCA2
  • BIRIP1
  • CDH1
  • CHEK2
  • EPCAM
  • MLH2
  • MSH6
  • NBN
  • NF1
  • PALB2
  • PMS2
  • PTEN
  • RAD51C
  • RAD51D
  • STK11
  • TP53

Applicable to cancer patients

Test procedure

*Product is for research use only.